Acumen Pharmaceuticals, Inc. (ABOS)

Market Cap	79.96M
Revenue (ttm)	n/a
Net Income (ttm)	-136.67M
Shares Out	60.57M
EPS (ttm)	-2.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,104
Open	1.270
Previous Close	1.250
Day's Range	1.260 - 1.320
52-Week Range	0.855 - 3.360
Beta	0.14
Analysts	Strong Buy
Price Target	8.00 (+506.06%)
Earnings Date	Nov 11, 2025

About ABOS

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 1, 2021
• Employees: 61
• Stock Exchange: NASDAQ
• Ticker Symbol: ABOS
• Website: https://acumenpharm.com

Analyst Summary

According to 3 analysts, the average rating for ABOS stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 506.06% from the latest price.

Price Target

$8.0

(506.06% upside)

Analyst Consensus: Strong Buy